ABBVIE, INC. for ABBVIE INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Implementation of H.R. 1, Bill to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 (bill formerly known as the Tax Cuts and Jobs Act) Draft legislation relating to economic activity in Puerto Rico
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| COURTNEY PIRON | — |
| STEPHEN SCANGO | — |
Copyright/Patent/Trademark CPT
S. 64, Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings Act of 2019 - Provisions related to patent settlements H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures Biopharmaceutical innovation and patent policy issues Patent litigation reform issues and issues related to post-grant proceeding at the PTO Value of intellectual property Patent protection
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| COURTNEY PIRON | — |
| STEPHEN SCANGO | — |
Medicare/Medicaid MMM
H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 475, RxCAP Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Part D policy issues including non-interference and rebates policy issues CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| HAYDEN RHUDY KENNEDY | — |
| COURTNEY PIRON | — |
| STEPHEN SCANGO | — |
Trade (domestic/foreign) TRD
Trade Agreements including NAFTA, USMCA and related policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| COURTNEY PIRON | — |
| STEPHEN SCANGO | — |
Health Issues HCR
H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems 340B drug discount program policy issues Drug cost and pricing policy issues Transparency policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| BINTA BEARD | — |
| HAYDEN RHUDY KENNEDY | — |
| COURTNEY PIRON | — |
| STEPHEN SCANGO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.